• Explore /
  • Poster
  • / Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.

Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.

Abstract Poster

Authors

null

Maya Kansara

Garvan Institute of Medical Research, Sydney, NSW, Australia

Maya Kansara , Frank Po-Yen Lin , Subotheni Thavaneswaran , Christine E Napier , John P. Grady , Mandy L. Ballinger , John Simes , David Morgan Thomas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Monotherapy

Clinical Trial Registration Number

ACTRN12616000908437

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2594)

DOI

10.1200/JCO.2023.41.16_suppl.2594

Abstract #

2594

Poster Bd #

436

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Genomic landscape and immune phenotype of malignant pleural mesothelioma.

Genomic landscape and immune phenotype of malignant pleural mesothelioma.

First Author: Meera Patel

First Author: Nikhil Pramod

First Author: Rebecca A Sager

First Author: Maroun Bou Zerdan